Healthcare Industry News: TYRX
News Release - July 23, 2013
TYRX Receives FDA Clearance for AIGISRx(R) Neuro Antibacterial EnvelopeExpands Access to Proven Antibacterial Technology to Neurosurgery
MONMOUTH JUNCTION, N.J.--(Healthcare Sales & Marketing Network)--TYRX, Inc. announced today that it has received U.S. Food and Drug Administration (FDA) clearance to market the AIGISRx Antibacterial Envelope for use with vagus nerve stimulators, which are currently used to treat seizure disorders and depression. This approval extends TYRX’s leadership in the commercialization of implantable medical devices designed to help reduce surgical-site infections (SSIs) associated with implantable devices into the field of neurosurgery.
The AIGISRx Antibacterial Envelope is intended to hold vagus nerve stimulators securely in place in order to provide a stable environment when implanted in the body. Additionally, the AIGISRx mesh envelope contains the antimicrobial agents rifampin and minocycline, which are released locally into the tissue in order to help reduce SSIs associated with vagus nerve stimulators implanted in the infraclavicular fossa.
“The AIGISRx Antibacterial Envelope provides neurosurgery patients and physicians with a new and proven infection prevention technology which can help improve patient outcomes,” stated Christopher Rumana, MD, FACS, Clinical Assistant Professor at Florida State University, and Chairman of Tallahassee Memorial Hospital Division of Neurosurgery.
“Securing the FDA-clearance to offer our AIGISRx technology to patients and physicians in the neurosurgery arena is an important milestone for TYRX and expands our leadership in the effort to reduce surgical site infections in multiple therapeutic areas of medical device implantation,” commented Robert White, TYRX President and Chief Executive Officer.
About TYRX, Inc.
TYRX, Inc. commercializes innovative, implantable combination drug+device products focused on infection control, including the AIGISRx Antibacterial Envelope, designed to reduce surgical site infections associated with Cardiac Implantable Electronic Devices (CIEDs). AIGISRx products contain the antimicrobial agents, rifampin and minocycline, which have been shown to reduce infection by pathogens responsible for the majority of CIED infections, including “superbugs” such as methicillin-resistant S. aureus (MRSA).*
For more information, please visit www.TYRX.com or www.HeartDeviceInfection.com.
*Data on file at TYRX and published Hansen et al. Pacing Clin Electrophysiol. 2009; 32(7):898-907.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.